Product Information
OTREXUP 20 MG/0.4 ML AUTO-INJ is a brand product labeled by Antares Pharma, Inc., priced at $480.8553 per ML under NDC 54436002004. Its NADAC has been published 203 times since Dec 23, 2015.
FDA first approved this application on Oct 11, 2013.
The High Outlier badge above means this manufacturer's average price in the methotrexate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
20 mg/.4mL
Manufacturer
Antares Pharma, Inc.NDC
54436002004
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
4/1/2025
Active Ingredients
METHOTREXATEApproval Type
New Drug (NDA)
FDA Application
NDA204824FDA Approved
10/11/2013
On Market Since
10/11/2013
Pharmacological Classes
Price Statistics
The NADAC for OTREXUP 20 MG/0.4 ML AUTO-INJ has been published 203 times since Dec 23, 2015, and over the history we have for it it has risen 42.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $480.8553 per ML |
|---|---|
| All-time high | $480.8553 (Apr 15, 2026) |
| All-time low | $337.2800 (Dec 23, 2015) |
| 52-week high | $480.8553 |
| 52-week low | $480.8553 |
| Median price | $466.5647 |
| Average price | $429.8682 |
| Largest weekly change | +18.3% (Apr 17, 2024) |
| Weeks tracked | 203 |
| Tracking since | Dec 23, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
0.0%
3Y
+21.9%
5Y
+21.9%
All
+42.6%
Last surveyed Apr 15, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Antares Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OTREXUP 20 MG/0.4 ML AUTO-INJ?
The current National Average Drug Acquisition Cost (NADAC) for OTREXUP 20 MG/0.4 ML AUTO-INJ, manufactured by Antares Pharma, Inc., is $480.8553 per ML (NDC 54436002004), effective Apr 15, 2026.
How has the price of OTREXUP 20 MG/0.4 ML AUTO-INJ changed over time?
Over the history we have for it, the NADAC for OTREXUP 20 MG/0.4 ML AUTO-INJ has risen 42.6%. It has been tracked across 203 weekly CMS publications since Dec 23, 2015.
What are the highest and lowest recorded NADAC prices for OTREXUP 20 MG/0.4 ML AUTO-INJ?
Since Dec 23, 2015, the NADAC for OTREXUP 20 MG/0.4 ML AUTO-INJ has ranged from a low of $337.2800 (Dec 23, 2015) to a high of $480.8553 (Apr 15, 2026), with a median of $466.5647 per ML.
Are there cheaper alternatives to OTREXUP 20 MG/0.4 ML AUTO-INJ?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RASUVO 20 MG/0.4 ML AUTOINJ, is $362.2851 per ML — about 25% below OTREXUP 20 MG/0.4 ML AUTO-INJ.
Who manufactures OTREXUP 20 MG/0.4 ML AUTO-INJ?
OTREXUP 20 MG/0.4 ML AUTO-INJ (NDC 54436002004) is labeled by Antares Pharma, Inc., and CMS classifies it as a brand product.